Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation

Annals of Neurology

Volumn 69, Issue 2, 2011, Pages 248-256

  Himeno, Eri ^a   Ohyagi, Yasumasa ^a   Ma, Linqing ^a   Nakamura, Norimichi ^a   Miyoshi, Katsue ^a   Sakae, Nobutaka ^a   Motomura, Kyoko ^a   Soejima, Naoko ^a   Yamasaki, Ryo ^a   Hashimoto, Tetsuya ^a   Tabira, Takeshi ^b   M Laferla, Frank ^c   Kira, Jun Ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOMORPHINE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; INSULINASE; PROTEASOME; PROTEIN P53; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; MEMORY DISORDER; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SHORT TERM MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOMORPHINE; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; IMMUNOHISTOCHEMISTRY; INSULYSIN; MAZE LEARNING; MEMORY, SHORT-TERM; MICE; MICE, TRANSGENIC; NEPRILYSIN; NEURONS; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 79952528559     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22319     Document Type: Article

References (54)

1. Golde TE, Dickson D, Hutton M., Filling the gaps in the Aβ cascade hypothesis of Alzheimer's disease. Curr Alzheimer Res 2006; 3: 421-430. (Pubitemid 46066421)
2. Selkoe DJ., Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106-113.
3. Sabbogh MN., Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009; 7: 167-185.
4. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Aβ42 immunization in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial. Lancet 2008; 372: 216-223. (Pubitemid 351978111)
5. Gouras GK, Almeida CG, Takahashi RH., Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 2005; 26: 1235-1244. (Pubitemid 41338539)
6. Chui DH, Tanahashi H, Ozawa K, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 1999; 5: 560-564. (Pubitemid 29220216)
7. Wirths O, Multhaup G, Czech C, et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 2001; 306: 116-120. (Pubitemid 32524311)
8. Oakley H, Cole SL, Logan S, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006; 26: 10129-10140. (Pubitemid 44527407)
9. Ohyagi Y., Intracellular amyloid β-protein as a therapeutic target for treating Alzheimer's disease. Curr Alzheimer Res 2008; 5: 555-561.
10. Stacy M, Silver D., Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 85-92.
11. Hsieh GC, Hollingsworth PR, Martino B, et al. Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther 2004; 308: 330-338. (Pubitemid 38090735)
12. Grünblatt E, Mandel S, Berkuzki T, Youdim MB., Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 1999; 14: 612-618. (Pubitemid 30011454)
13. Grünblatt E, Mandel S, Gassen M, Youdim MB., Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl 1999; 55: 57-70. (Pubitemid 29195797)
14. Grünblatt E, Mandel S, Maor G, Youdim MB., Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J Neurochem 2001; 77: 146-156. (Pubitemid 32245088)
15. Mandel S, Maor G, Youdim MB., Iron and α-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci 2004; 24: 401-416. (Pubitemid 41389377)
16. Castri P, Busceti C, Battaglia G, et al. Protection by apomorphine in two independent models of acute inhibition of oxidative metabolism in rodents. Clin Exp Hypertens 2006; 28: 387-394. (Pubitemid 44178516)
17. Hara H, Ohta M, Adachi T., Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 2006; 84: 860-866. (Pubitemid 44366687)
18. Morelira PI, Smith MA, Zhu X, et al. Therapeutic potential of oxidant mechanisms in Alzheimer's disease. Expert Rev Neurother 2004; 4: 995-1004. (Pubitemid 39482272)
19. Lashuel HA, Hartley DM, Balakhaneh D, et al. New class of inhibitors of amyloid-β fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem 2002; 277: 42881-42890. (Pubitemid 35285665)
20. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003; 39: 409-421. (Pubitemid 36937044)
21. Billings LM, Oddo S, Green KN, et al. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45: 675-688. (Pubitemid 40320703)
22. Caccamo A, Oddo S, Tran LX, LaFerla FM., Lithium reduces tau phosphorylation but not Aβ or working memory deficit in a transgenic model with both plaques and tangles. Am J Pathol 2007; 170: 1669-1675. (Pubitemid 47339311)
23. McKee AC, Carreras I, Hossain L, et al. Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008; 1207: 225-236.
24. McAlpine FE, Lee JK, Harms AS, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009; 34: 163-177.
25. Guan H, Liu Y, Daily A, et al. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res 2009; 87: 1462-1473.
26. Ohyagi Y, Tsuruta Y, Motomura K, et al. Intraneuronal amyloid β42 enhanced by heating but counteracted by formic acid. J Neurosci Methods 2007; 159: 134-138. (Pubitemid 44792267)
27. Ohyagi Y, Asahara H, Chui DH, et al. Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J 2005; 19: 255-257. (Pubitemid 40189273)
28. Ma L, Ohyagi Y, Miyoshi K, et al. Increase in p53 protein levels by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J Alzheimers Dis 2009; 16: 565-575.
29. Iwata N, Takaki Y, Fukami S, et al. Region-specific reduction of Aβ-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 2002; 70: 493-500. (Pubitemid 35222386)
30. Takeda K, Araki W, Tabira T., Enhanced generation of intracellular Aβ42 amyloid peptide by mutation of presenilins PS1 and PS2. Eur J Neurosci 2004; 19: 258-264. (Pubitemid 38177864)
31. Miyoshi K, Ohyagi Y, Sakae N, et al. Enhancement of activation of caspases by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J Alzheimers Dis 2009; 16: 551-564.
32. Anderson DW, Bradbury KA, Schneider JS., Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 2006; 24: 3174-3182. (Pubitemid 44952649)
33. Franberg J, Karlström H, Winblad B, et al. γ-Secretase dependent production of intracellular domains is reduced in adult compared to embryonic rat brain membranes. PLoS ONE 2010; 5: e9772.
34. Lopez Salon M, Pasquini L, Besio Moreno M, et al. Relationship between β-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 2003; 180: 131-143. (Pubitemid 36398168)
35. Wang DS, Dickson DW, Malter JS., β-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006; 2006: 1-12.
36. Smith MA, Hirai K, Hsiao K, et al. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998; 70: 2212-2215. (Pubitemid 28207848)
37. Oddo S, Vasilevko V, Caccamo A, et al. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006; 281: 39413-39423. (Pubitemid 46041901)
38. Tamagno E, Gugliemotto M, Aragno M, et al. Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein. J Neurochem 2008; 104: 683-695.
39. Gomez-Ramos A, Diaz-Nido J, Smith MA, et al. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003; 71: 863-870. (Pubitemid 36293007)
40. Su B, Wang X, Lee HG, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci Lett 2010; 468: 267-271.
41. Pappolla MA, Chyan Y-J, Omar RA, et al. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998; 152: 871-877. (Pubitemid 28173347)
42. Ohyagi Y, Tabira T., Intracellular amyloid β-protein and its associated molecules in the pathogenesis of Alzheimer's disease. Mini Rev Med Chem 2006; 6: 1075-1080. (Pubitemid 44524450)
43. Oddo S, Caccamo A, Tran L, et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J Biol Chem 2006; 281: 1599-1604.
44. Oddo S, Caccamo A, Tseng B, et al. Blocking Aβ42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein 70-interacting protein: a mechanistic link between Aβ and tau pathology. J Neurosci 2008; 28: 12163-12175.
45. Oddo S, Caccamo A, Cheng D, LaFerla FM., Genetically altering Aβ distribution from the brain to vasculature ameliorates tau pathology. Brain Pathol 2009; 19: 421-430.
46. Takahashi RH, Almeida CG, Kearney PF, et al. Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 2004; 24: 3592-3599. (Pubitemid 38481116)
47. Oddo S, Caccamo A, Smith IF, et al. A dynamic relationship between intracellular and extracellular pools of Aβ. Am J Pathol 2006; 168: 184-194. (Pubitemid 43062572)
48. LaFerla FM, Green KN, Oddo S., Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
49. Oddo S., The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 2008; 12: 363-373. (Pubitemid 351555121)
50. Tseng BP, Green KN, Chan JL, et al. Aβ inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 2007; 29: 1607-1618.
51. Ishige K, Chen Q, Sagara Y, Schubert D., The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. J Neurosci 2001; 21: 6069-6076. (Pubitemid 32737740)
52. Lebel M, Patenaude C, Allyson J, et al. Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways. Neuropharmacology 2009; 57: 392-402.
53. Yurko-Mauro KA, Friedman E., Dopamine receptor stimulation decreases cytosolic γ protein kinase C immunoreactivity in rat hippocampal slices: evidence for increased Ca2+-dependent proteolysis. J Neurochem 1995; 65: 1622-1630.
54. Da Cruz e Silva OA, Rebelo S, Vieira SI, et al. Enhanced generation of Alzheimer's amyloid-β following chronic exposure to phorbol ester correlates with differential effects on α and ε isozymes of protein kinase C. J Neurochem 2009; 108: 319-330.